Connection

Elizabeth Garrett-Mayer to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Prostatic Neoplasms.
Elizabeth Garrett-Mayer
Connection Strength
0.955
Prostatic Neoplasms
  1. Evaluating an intervention to increase cancer knowledge in racially diverse communities in South Carolina. Patient Educ Couns. 2011 May; 83(2):256-60.
    View in: PubMed
    Score: 0.231
  2. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol. 2013 Jul; 136:233-7.
    View in: PubMed
    Score: 0.068
  3. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24.
    View in: PubMed
    Score: 0.065
  4. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
    View in: PubMed
    Score: 0.062
  5. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology. 2010 Nov; 76(5):1162-7.
    View in: PubMed
    Score: 0.059
  6. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010 Jan 01; 16(1):203-11.
    View in: PubMed
    Score: 0.055
  7. Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2008 May 07; 100(9):681-2; author reply 682-3.
    View in: PubMed
    Score: 0.049
  8. Effect of DNA methylation on identification of aggressive prostate cancer. Urology. 2008 Dec; 72(6):1234-9.
    View in: PubMed
    Score: 0.049
  9. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol. 2007 Nov 01; 25(31):4998-5008.
    View in: PubMed
    Score: 0.048
  10. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007 Nov 01; 13(21):6396-403.
    View in: PubMed
    Score: 0.048
  11. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 01; 25(25):3965-70.
    View in: PubMed
    Score: 0.047
  12. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
    View in: PubMed
    Score: 0.046
  13. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar 07; 99(5):376-85.
    View in: PubMed
    Score: 0.046
  14. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007 Mar; 69(3):526-31.
    View in: PubMed
    Score: 0.046
  15. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003 Jul 02; 95(13):990-1000.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.